Table 1 Characteristics of 11 included studies
Study (year) | Region | No. of patients (female %) | Study design | Age | Therapy line | Dosage of Osimertinib (mg) | T790M status | LM response assessment criteria | Follow-up (mo.) |
|---|---|---|---|---|---|---|---|---|---|
Yang 2019 | Asian | 41 (71%) | Phase I | 59 (44–75) |  ≥ 2 | 160 mg | Positive:22; negative:13; unknown:6 | RANO-LM (BICR) | 9.9 |
Lee 2020 | Asian | 110 (62%) | Retrospective | 58 (39–75) |  ≥ 2 | 80 mg (n = 67); 160 mg (n = 43) | Positive:60; negative:37; unknown:13 | NA | NA |
Ahn 2020 | Global | 22 (59%) | Retrospective pooled analysis of 4 prospective studies | 58 (36–80) |  ≥ 2 | 80 mg | 100% positive | RANO-LM (BICR) | 11.7 |
Park 2020 | Asian | 40 (60%) | Phase II | 59 (38–77) |  ≥ 2 | 160 mg | 100% positive | RECIST 1.1 | 9.6 |
Nanjo 2017 | Asian | 13 (62%) | Prospective pilot study | 67 (54–79) |  ≥ 5 | 80 mg | 100% positive | CNS radiographic change | NA |
Zheng 2020 | Asian | 45 (60%) | Retrospective | 54 (22–82) | 1(16%); ≥ 2(84%) | 80 mg | Positive:9; negative:36 | RANO-LM | NA |
Saboundji 2018 | Europe | 20 (70%) | Retrospective | 61.2 (11.2) |  ≥ 2 | 80 mg (17); 160 mg (2); 40 mg (1) | 65% positive | NA | 11.1 |
Reungwetwattana 2018 | Global | 5 (NA) | Preplanned, exploratory analysis of FLAURA | NA | 1 | 80Â mg | 0% | RECIST 1.1 | NA |
Akazawa 2019 | Asian | 6 (50%) | Phase II | 61.5 (50–75) |  ≥ 2 | 80 mg | 100% | Radiological response | NA |
Ahn 2019 | Asian | 40 (NA) | Phase II | NA |  ≥ 2 | 80 mg: 16; 160 mg: 24 | 100% | NA | 8.3 |
Andrew 2020 | American | 11 | Retrospective | NA |  ≥ 2 | 160 mg | NA | NA | NA |